The latest innovations in the drug pipeline for multiple sclerosis

American Health and Drug Benefits

Volumn 8, Issue 8, 2015, Pages 448-453

  Radick, Lea ^a   Mehr, Stanton R ^b  

^a SM Health Communications ^*  (United States)

^b SM Health Communications   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DACLIZUMAB; FINGOLIMOD; FUMARIC ACID DIMETHYL ESTER; GLATIRAMER; IMMUNOMODULATING AGENT; LAQUINIMOD; MASITINIB; NEW DRUG; OCRELIZUMAB; OFATUMUMAB; OZANIMOD; PEGINTERFERON BETA1A; PONESIMOD; SIPONIMOD; SPHINGOSINE 1 PHOSPHATE RECEPTOR;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; CLINICAL TRIAL (TOPIC); CONTROLLED CLINICAL TRIAL (TOPIC); DRUG APPROVAL; DRUG EFFICACY; DRUG TARGETING; FOOD AND DRUG ADMINISTRATION; HUMAN; MULTICENTER STUDY (TOPIC); MULTIPLE SCLEROSIS; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC);

EID: 84951942716     PISSN: 19422962     EISSN: 19422970     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. National Multiple Sclerosis Society. What is MS? 2015. www.nationalmssociety.org/What-is-MS. Accessed September 28, 2015.
2. Biogen Idec. Avonex prescribing information. August 2014. www.avonex.com/pdfs/Avonex_Prescribing_Information.pdf. Accessed September 27, 2015.
3. Biogen Idec. Biogen Idec's Plegridy (peginterferon beta-1a) approved in the US for the treatment of multiple sclerosis. Press release. August 15, 2014. http://media.biogen.com/press-release/multiple-sclerosis-ms/biogen-idecs-plegridypeginterferon-beta-1a-approved-us-treatment. Accessed September 27, 2015.
4. Biogen Idec. Plegridy prescribing information. August 2014. www.plegridy.com/pdfs/plegridy-prescribing-information.pdf. Accessed September 27, 2015.
5. Calabresi PA, Kieseier BC, Arnold DL, et al. Pegylated interferon ß-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study. Lancet Neurol. 2014;13:657-665.
6. Kieseier BC, Arnold DL, Balcer LJ, et al. Peginterferon beta-1a in multiple sclerosis: 2-year results from ADVANCE. Mult Scler J. 2015;21:1025-1035.
7. Kita M, Fox RJ, Gold R, et al. Effects of delayed-release dimethyl fumarate (DMF) on health-related quality of life in patients with relapsing-remitting multiple sclerosis: an integrated analysis of the phase 3 DEFINE and CONFIRM studies. CUn Ther. 2014;36:1958-1971.
8. Fox RJ, Miller DH, Phillips JT, et al. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med. 2012;367:1087-1097.
9. Gold R, Kappos L, Arnold DL, et al. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med. 2012;367:1098-1107.
10. Havrdova E, Hutchinson M, Kurukulasuriya NC. Oral BG-12 (dimethyl fumarate) for relapsing-remitting multiple sclerosis: a review of DEFINE and CONFIRM. Evaluation of: Gold R, Kappos L, Arnold D, et al. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med. 2012;367:1098-1107
11. Fox RJ, Miller DH, Phillips JT, et al. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med. 2012;367:1087-197. Expert Opin Pharmacother. 2013;14:2145-2156.
12. Biogen Idec. New data from ENDORSE show positive results continued over five years with Tecfidera® (dimethyl fumarate) in a wide range of multiple sclerosis patients. Press release. September 11, 2014. www.businesswire.com/news/home/20140911005143/en/Data-ENDORSE-Show-Positive-Results-Continued-Years#.ViD_7vlVhHw. Accessed October 16, 2015.
13. Biogen Idec. FDA accepts biologics license application for Zinbryta (dac-lizumab high-yield process) for treatment of MS. Press release. April 29, 2015. http://media.biogen.com/press-release/corporate/fda-accepts-biologics-license-application-zinbryta-daclizumab-high-yield-pro. Accessed September 27, 2015.
14. Kappos L, Wiendl H, Selmaj K, et al. Daclizumab HYP versus interferon beta-1a in relapsing multiple sclerosis. N Engl J Med. 2015;373:1418-1428.
15. ClinicalTrials.gov. Long-term extension study in participants with multiple sclerosis who have completed Study 205MS301 (NCT01064401) to evaluate the safety and efficacy of BIIB019 (EXTEND). September 2015. www.clinicaltrials.gov/ct2/show/NCT01797965?no_unk=Yandcond=multiple+sclerosisandphase= 2andlup_s=12%2F01%2F2014andlup_e=09%2F29%2F2015andrank=7. Accessed September 29, 2015.
16. AB Science. AB Science announces cessation of its rheumatoid arthritis study in order to focus on clinical studies with a probability of success greater than 50%. Press release. http://ab-science.com/file_bdd/content/1442852040_RationalisationPipelinevEn.pdf. Accessed October 16, 2015.
17. AB Science. Masitinib in progressive forms of multiple sclerosis. July 2015. http://ab-science.com/file_bdd/content/1438102350_MSPresentationvJuly2015.pdf. Accessed September 27, 2015.
18. Newman N. Masitinib shows promise in study for treating progressive MS patients. Multiple Sclerosis News Today. July 25, 2015. http://multiplesclerosisnewstoday.com/2015/07/24/masitinib-shows-promise-study-treating-progressive-ms-patients/. Accessed October 16, 2015.
19. Comi G, Pulizzi A, Rovaris M, et al; LAQ/5062 Study Group. Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study. Lancet. 2008;371:2085-2092.
20. Comi G, Abramsky O, Arbizu T, et al; LAQ/5063 Study Group. Oral laqui-nimod in patients with relapsing-remitting multiple sclerosis: 36-week doubleblind active extension of the multi-centre, randomized, double-blind, parallel-group placebo-controlled study. Mult Scler. 2010;16:1360-1366.
21. Comi G, Jeffery D, Kappos L, et al. Placebo-controlled trial of oral laquini-mod for multiple sclerosis. N Engl J Med. 2012;366:1000-1009.
22. Vollmer TL, Sorensen PS, Selmaj K, et al; BRAVO Study Group. A randomized placebo-controlled phase III trial of oral laquinimod for multiple sclerosis. J Neurol. 2014;261:773-783.
23. MultipleSclerosis.net. Laquimod for MS. 2012. http://multiplesclerosis.net/research/laquinimod/. Accessed October 16, 2015.
24. Multiple Sclerosis Society. Laquinimod turned down for a European licence. June 18, 2014. www.mssociety.org.uk/ms-news/2014/06/laquinimod-turned-down-european-licence. Accessed October 16, 2015.
25. Olsson T, Boster A, Fernández Ó, et al. Oral ponesimod in relapsing-remitting multiple sclerosis: a randomised phase II trial. J Neurol Neurosurg Psychiatry. 2014; 85:1198-1208.
26. ClinicalTrials.gov. Oral ponesimod versus teriflunomide in relapsing multiple sclerosis (OPTIMUM). August 26, 2015. https://clinicaltrials.gov/ct2/show/NCT02425644?term=ponesimodandrank=4. Accessed October 16, 2015.
27. Selmaj K, Li DK, Hartung HP, et al. Siponimod for patients with relapsing-remitting multiple sclerosis (BOLD): an adaptive, dose-ranging, randomised, phase 2 study. Lancet. 2013;12:756-767.
28. ClinicalTrials.gov. Exploring the efficacy and safety of siponimod in patients with secondary progressive multiple sclerosis (EXPAND). August 18, 2015. www.clinicaltrials.gov/ct2/show/NCT01665144?no_unk=Yandcond=multiple+sclerosisandphase=2andlup_s=12%2F01%2F2014andlup_e=09%2F29%2F2015andrank=21. Accessed September 27, 2015.
29. Science Daily. Multiple sclerosis drug candidate shows new promise. September 19, 2014. www.sciencedaily.com/releases/2014/09/140919092755.htm. Accessed October 12, 2015.
30. Moore C. Celgene to acquire Receptos, advancing leadership in immune-inflammatory diseases such as MS and IBD. Multiple Sclerosis News Today. July 17, 2015. http://multiplesclerosisnewstoday.com/2015/07/17/celgene-acquire-receptos-advancing-leadership-immune-inflammatory-diseases-ms-ibd/. Accessed September 25, 2015.
31. ClinicalTrials.gov. Efficacy and safety study of RPC1063 in relapsing multiple sclerosis (Radiance Study). April 14, 2015. www.clinicaltrials.gov/ct2/show/NCT02047734?no_unk=Yandcond=multiple+sclerosisandphase=2andlup_s=12%2F01%2F2014andlup_e=09%2F29%2F2015andrank=55. Accessed September 27, 2015.
32. Kappos L, Li D, Calabresi PA, et al. Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial. Lancet. 2011;378:1779-1787.
33. Silva P. Could Genentech's ocrelizumab become the first effective primary progressive MS therapy? Multiple Sclerosis News Today. September 29, 2015. http://multiplesclerosisnewstoday.com/2015/09/29/genentechs-ocrelizumab-become-first-effective-primary-progressive-ms-therapy/. Accessed September 29, 2015.
34. ClinicalTrials.gov. Natalizumab and multiple sclerosis. October 18, 2015. www.clinicaltrials.gov/ct2/results?term=natalizumab+AND+multiple+sclerosisandrecr=andrslt=andtype=andcond=andintr=andtitles=andoutc=andspons=andlead=andid=andstate1=andcntry1=andstate2=andcntry2=andstate3=andcntry3=andlocn=andgndr=andphase=1andphase=2andrcv_s=andrcv_e=andlup_s=andlup_e=. Accessed October 18, 2015.
35. Novartis. Novartis acquires all remaining rights to GSK's ofatumumab to develop treatments for MS and other autoimmune indications. Press release. August 21, 2015. www.novartis.com/news/media-releases/novartis-acquires-all-remaining-rights-gsks-ofatumumab-develop-treatments-ms-and. Accessed September 29, 2015.
36. ClinicalTrials.gov. ACTH for fatigue in multiple sclerosis patients. May 13, 2015. www.clinicaltrials.gov/ct2/show/NCT02315872?no_unk=Yandcond=multiple+sclerosisandphase=2andlup_s=12%2F01%2F2014andlup_e=09%2F29%2F2015andrank=10. Accessed September 29, 2015.
37. Multiple Sclerosis Society. MD1003. 2015. http://mssociety.org.uk/node/691218. Accessed September 28, 2015.
38. Tourbah A, Lebrun-Frenay C, Edan G. MD1003 (high doses of biotin) in progressive multiple sclerosis: subgroup analyses of the MS-SPI trial. Presented at the 2015 annual meeting of the European Committee for Treatment and Research in Multiple Sclerosis; October 7-10, 2015; Barcelona, Spain. http://onlinelibrary.ectrims-congress.eu/ectrims/2015/31st/116698/tourbah.ayman. md1003.(high.doses.of.biotin).in.progressive.multiple.sclerosis.html?f=m3. Accessed October 19, 2015.